1. KRAS Mutations Match in Primary Tumour and Liver Mets 2. Administering Folfox 6 with Avastin in Non-optimally resectable Liver Mets 3. Effect of Simvastatin on Erbitux Resistance with KRAS Mutations 4. Addressing the Hypersensitivity to Cold Caused by Oxaliplatin 5. Venlafaxine for the Prevention of Oxaliplatin-Induced Neuropathy 6. Stronger Chemo + Immune Boost May Help Metastatic Colorecta...

Bioprinting offers the ability to create highly complex 3D architectures with living cells. This cutting-edge technique has significantly gained popularity and applicability in several fields. Bioprinting methods have been developed to effectively and rapidly pattern living cells, biological macromolecules, and biomaterials. These technologies hold great potential for applications in cancer res...

1. Prostate Cancer Hormone Treatments May Increase Risk of Colorectal Cancer 2. DCA May Be Problematic for The Treatment of Colorectal Cancer 3. Erbitux Administered Every Two Weeks in Advanced Colorectal Cancer 4. Using Patients’ Own Tumour Cells to Create Effective Cancer Vaccine 5. Guiding Treatment in Stage II Colon Cancer 6. 2010 Advances for the Treatment of Colon Cancer 7. COX-2 In...

Koichi Sugimoto1,2 Nobutaka Shimizu1 Takashi Oki2 Kazuhiro Nose2 Tsukasa Nishioka2 Shogo Adomi3 Takayuki Ohzeki3 Atsunobu Esa3 Hirotsugu Uemura1 1Department of Urology, Kinki University Faculty of Medicine, OsakaSayama, Osaka, Japan; 2Department of Urology, Sakai Hospital Kinki University Faculty of Medicine, Sakai, Osaka, Japan; 3Department of Urology, NTT West Osaka Hospital, Osaka, Osaka, Japan

Cancer is one of the major diseases that limited the human life; it is treated with surgery, radiation, chemotherapy, hormones, and immunotherapy. According to estimates from the International Agency for Research on Cancer (IARC), there were 12.7 million new cancer cases in 2008 worldwide. The corresponding estimates for total cancer deaths in 2008 were 7.6 million (about 21,000 cancer deaths a...

In 1950, in the fIrst important deviation from previous custom, Dr. Aub devoted his address, entitled “This Business of Cancer Research,―to a consideration of the effects on the research community of extensive public support of cancer research. Prior to that time the Association from time to time did consider and express opinions on issues of broad import, but the tendency, as of most scien...

ln 1969, the International Agency for Research on Cancer (IARC) initiated a programme to evaluate the carcinogenic risk of chemicals to humans and to produce monographs on individua1 chemica1s. The MOl1ographs programme has since been expanded to include consideration of exposures to comp1ex mixtures of chemica1s (which occur, for example, in sorne occupations and as a result of human habits) a...